Artal Group’s AnaptysBio ANAB Stock Holding History

Artal Group’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-150,000	Closed	-$9.57M	–	106
2018 Q4	$9.57M	Sell	150,000 -150,000	-50%	-$11.2M	0.35%	48
2018 Q3	$29.9M	Buy	300,000 +100,000	+50%	+$8.3M	0.78%	21
2018 Q2	$14.2M	Buy	200,000 +10,000	+5%	+$839K	0.3%	36
2018 Q1	$19.8M	Buy	190,000 +40,000	+27%	+$4.51M	0.25%	31
2017 Q4	$15.1M	Hold	150,000	–	–	0.23%	38
2017 Q3	$5.24M	Sell	150,000 -100,000	-40%	-$2.7M	0.09%	63
2017 Q2	$5.98M	Buy	250,000 +205,310	+459%	+$5.16M	0.1%	53
2017 Q1	$1.24M	Buy	+44,690	New	+$1.04M	0.03%	86

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Artal Group's ANAB Position: Q1 2019 in Review

Artal Group sold out of AnaptysBio (ANAB) in Q1 2019, closing a stake of 150,000 shares — an estimated $9.57M sold.

Artal Group first reported a position in ANAB in Q1 2017 and held it in 8 quarters. The position peaked at $29.9M in Q3 2018. 129 funds tracked by Wall St. Rank hold ANAB as of Q1 2019.

Artal Group reported no remaining AnaptysBio position as of Q1 2019 after selling out during the quarter.
Artal Group sold 150,000 AnaptysBio shares in Q1 2019, an estimated $9.57M.
Artal Group first reported a position in AnaptysBio in Q1 2017 and held it in 8 quarters.
Artal Group's AnaptysBio position peaked at $29.9M in Q3 2018.
129 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2019.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.